Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00519857 | Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468) | PHASE3 | COMPLETED | 4,534 | — | — | Jul 1, 2001 | Aug 1, 2006 | Feb 3, 2022 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Tibolone |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Tibolone | DRUG | 1.25 mg p.o, once daily for 3 years |
| Placebo | DRUG | Tablet p.o, once daily for 3 years |
Inclusion Criteria: * Voluntary written informed consent, and who were willing and able to make reasonable efforts to observe all clinical trial requirements were to be enrolled * Subjects were to be postmenopausal (naturally or surgically) women, from 60 to 85 years of age (inclusive) at entry * S...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | NA | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | — | Undisclosed |